Version 1

1.2b: 09-Fe

A R

b-2016

Random

m

Die

This sIde

mizEd Tri

minimIZ

etitiIntended A

study is regisentification n

ial of EN

ZE Therm

an M

Audience: Di

stered at Clinnumber NCT

NtERal G

mal Injur

Manietitians

nicaltrials.goT00985205

Glutamin

ry

nual

ov.

1

ne to

l

Version 1

Table oDocumen

Study Co

Glossary

Study Sy

Overvie

Study D

Setting

Study P

Study I

Outcom

Trial Du

Study

Estima

Diagram

Training .

Patient P

Inclusio

Exclusio

Investiga

Nutrest

Maltrin

Dosing

Duration

Standard

1) Pr

2) Pr

3) Vit

4) Sp

1.2b: 09-Fe

of Contennt History ...

ontacts ........

y ..................

ynopsis .......

ew ................

Design...........

....................

Population ....

ntervention .

mes ...............

uration .........

Recruitment

ated Total Stu

m of Study Ov

...................

Population ...

on Criteria ....

on Criteria ....

ational Produ

tore (L Glut

n® M100 Malt

....................

..................

dization of N

escribed Ene

escribed Prot

tamin & Mine

pecialized nut

b-2016

nts ...................

...................

...................

...................

.....................

.....................

.....................

.....................

.....................

.....................

.....................

Period ..........

udy Duration .

verview ........

...................

...................

.....................

.....................

uct ...............

tamine) .........

todextrin (con

.....................

...................

utrition Prac

rgy needs .....

tein needs ....

eral Prescript

tritional form

...................

...................

...................

...................

.....................

.....................

.....................

.....................

.....................

.....................

.....................

.....................

.....................

.....................

...................

...................

.....................

.....................

...................

.....................

ntrol) ............

.....................

...................

ctices ...........

.....................

.....................

tion ...............

ulas ..............

...................

...................

...................

...................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

...................

...................

......................

......................

...................

......................

......................

......................

...................

...................

......................

......................

......................

......................

...................

...................

...................

...................

.....................

.....................

.....................

.....................

.....................

.....................

.....................

.....................

.....................

.....................

...................

...................

.....................

.....................

...................

.....................

.....................

.....................

...................

...................

.....................

.....................

.....................

.....................

...................

...................

...................

...................

.....................

.....................

.....................

.....................

.....................

.....................

.....................

.....................

.....................

.....................

...................

...................

.....................

.....................

...................

.....................

.....................

.....................

...................

...................

.....................

.....................

.....................

.....................

2

...................

...................

...................

...................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

...................

...................

......................

......................

...................

......................

......................

......................

...................

...................

......................

......................

......................

......................

...... 4

...... 4

...... 5

...... 6

....... 6

....... 6

....... 6

....... 6

....... 6

....... 6

....... 7

....... 7

....... 7

....... 7

...... 8

...... 8

....... 8

....... 8

...... 9

....... 9

....... 9

..... 10

.... 10

.... 10

..... 11

..... 11

..... 11

..... 12

Version 1

5) Op

6) Gl

Data Col

Nutritio

Daily N

Appendic

Append

Append

Append

Referenc

1.2b: 09-Fe

ptimization of

ycemic contr

lection ........

on Assessmen

utrition Rece

ces .............

dix A: Enteral

dix B: Nutritio

dix C: Daily Nu

ces ..............

b-2016

f the Delivery

ol .................

...................

nt/Timing (se

eived (see App

...................

Feeding Prot

on Assessmen

utrition Form

...................

y of Enteral N

.....................

...................

e Appendix B

pendix C) ......

...................

tocol .............

nt/Timing For

m ....................

...................

utrition ........

......................

...................

B) ...................

......................

...................

......................

rm .................

......................

...................

.....................

.....................

...................

.....................

.....................

...................

.....................

.....................

.....................

...................

.....................

.....................

...................

.....................

.....................

...................

.....................

.....................

.....................

...................

3

......................

......................

...................

......................

......................

...................

......................

......................

......................

...................

..... 12

..... 12

.... 13

..... 13

..... 14

.... 16

..... 17

..... 18

..... 19

.... 20

Version 1

Docum

Version:Version 1Version 1Version 1

Study Name Dr. Dare

Maureen

IT Help D

All quest In the evInvestigaOperatio

1.2b: 09-Fe

ment Histo

: Date 1: 10 Dece1.1: 29 Janu1.2: 09 Feb

Contacts

n Heyland

n Dansereau

Desk

ions related

ent you are ator (PI). If yons Manager

b-2016

ory

mber 2015 uary 2016 ruary 2016

s

Role Principal Coordinat

Project Le

http://www

to study pro

unable to reou are unabr.

Investigatorting Investig

eader

w.ceru.ca/he

ocedures sho

each the Prole to reach e

SupersedOriginal ve10 Decem29 January

Co,

gator dkCeFa daoffce Fore JaCEovoff

elpdesk/ope

ould be dire

oject Leader,either the PL

ed Version ersion ber 2015 y 2016

ontact Detakh2@ queenell: +1403-91ax: +1613-54

anserem@kgfice: +1613-5

ell: +1613-88

or urgent issach PL or P

anet OvervelERU Operatvervelj@kghfice: +1613-5

n.php

cted to the P

, please conL or PI, pleas

(Date)

ails nsu.ca 15-5573 48-2428

gh.kari.net 549-6666 ex88-4320

sues, if unaPI:

de tions Manag.kari.net 549-6666 ex

Project Lead

tact the Prinse contact th

4

xt. 6686

able to

er

xt. 6241

der (PL).

ncipal he CERU

Version 1

Glossa ACU CERU CRF/eCR CV DAL EDCS EN FDA GCP HC hCG HOB IP PL PN RC REDCap SAE SD SI Sub-I po

1.2b: 09-Fe

ary

Acute

Clinica

RF Case

Curric

Deleg

Electr

Entera

Food

Good

Health

Huma

Head

Invest

Projec

Paren

Resea

p™ Resea

Seriou

Study

Site In

Sub-In

per os

b-2016

e Care Unit (

al Evaluation

Report Form

culum Vitae

gation of Aut

ronic Data C

al Nutrition

and Drug Ad

Clinical Pra

h Canada

an Chorionic

of Bed

tigational Pro

ct Leader or

nteral Nutritio

arch Coordin

arch Electro

us Adverse E

y Day

nvestigator

nvestigator

s (by mouth)

ICU or Burn

n Research

m/electronic

hority Log

Capture Syste

dministration

actice

Gonadotrop

oduct

delegate

on

nator

nic Data Ca

Event

)

Unit)

Unit at King

Case Repo

em

n (USA)

pin (pregnan

pture system

gston Genera

rt Form

ncy indicator

m

al Hospital (

r)

5

Methods Ceentre)

Version 1

Study OverviewThe primenteral gWe asseacquired hospital l Study DeA large, msevere b Setting ApproximEurope. Study Po2700 aduage 18 –inhalationwe requi Study InPatients 4 hours, operationunit, wha OutcomePrimary o Seconda Tertiary o

1.2b: 09-Fe

Synopsis

w mary purpose

lutamine adert that glutam

blood strealength of sta

esign multicenter, urns random

mately 60 ter

opulation ult patients w

– 59 years wen injury, a mre a TBSA ≥

ntervention will receive or orally 3 –

n, or discharatever comes

es outcome:

ary outcome:

outcomes:

b-2016

s

e of this studministration mine adminim infections

ay, and impro

double-blindmly allocated

rtiary acute c

with deep 2nd

e require a Tminimum of 1≥ 10%.

glutamine o– 4 times a drge from the s first.

6-month m

: Time to dis

Health-relaIncidence Hospital mDuration oAcute careHospital le

dy is to deterto severely stration will

s from Gram ove the phys

d, pragmaticd to receive e

care burn ce

d and/or 3rd dTBSA (Total5 % TBSA i

r maltodextray, for a totaacute care

mortality

scharge aliv

ated quality of acquired

mortality of mechanicae unit lengthength of stay

rmine the ovburn injureddecrease 6 negative or

sical function

c, randomizeenteral gluta

entres in Can

degree burn Burn Surfacs acceptable

rin (placebo/al of 0.5 g/kgunit, or 3 mo

ve

of life with pbacteremia

al ventilation of stay

y

verall treatmed patients in month morta

rganisms, ren of survivin

ed controlledamine or pla

nada, the Un

ns requiring sce Area) ≥ 2e. For patien

/control) throg/day until 7onths after a

particular focdue to Gram

n

ent effect anacute care uality, decrea

educe acute g burn injure

d trial of 2700cebo.

nited States,

skin grafting20%, or in thnts aged 60

ough their fe days after t

admission to

cus on physim negative o

6

nd safety of units (ACUs

ase hospital-care unit aned patients.

0 patients w

, Australia a

. For patiente presence years or old

eding tube etheir last gra the acute c

cal functionorganisms

s). -d

with

nd

ts of an

der

every afting are

Version 1

Trial DurStudy Re4 years -study. EstimateWe antic 6 month 4 year re6 month

DiagramBelow is sections

1.2b: 09-Fe

ration ecruitment P- based on a

ed Total Studcipate the tot

Start-up perecruitment pefollow-up pe

m of Study Oa diagrammof the Study

b-2016

Period approximatel

dy Duration tal study dur

riod eriod eriod

Overview matic represey Procedures

y 1 patient p

ration to be 5

entation of ths Manual for

per site per m

5 years, brok

he RE-ENERr comprehen

month, as de

ken down as

RGIZE Studynsive instruc

emonstrated

s follows:

y. Refer to actions for stu

7

d in the pilot

appropriate udy activities

s.

Version 1

Trainin Each meexperienresponsi Each Dietraining w

Patient Inclusio

1) DTa

2) P

Exclusio

1) >Tclhyo

2) P

3) Incr4 In>2

P

4) L

5) Pa

6) C(B

7) P

1.2b: 09-Fe

ng

ember of the ce to assumble for ensu

etitian must will be provid

t Populat

n Criteria Deep 2nd andThe presence

ssessment t

Patient meeta. Patienb. Patienc. Patien

on Criteria 72 hours fro

This refers tolock starts foas been an our unit.

Patients youn

n patients wireatinine >1hours if a 2

n patients wi80 mmol/L f4 hours (or 8

Patients with

iver cirrhosis

Pregnancy (uge by each s

Contra-indicaBeing NPO i

Patients with

b-2016

site researcme responsib

ring that s/h

have documded by CERU

tion

d/or deep 3r

e of deep 2nthat must be

ts one of thnts 18 – 59 ynts 18 – 59 ynts > 60 yea

om admissioo admission torm the timeextended pe

nger than 18

ithout know71 mmol/L o4 hour perio

ith acute onfrom baselin80 ml/last 4

chronic ren

s -Child’s cla

urine/blood tesite as part o

ation for EN: s not consid

injuries from

ch team shoubility for the pe and the lo

mented trainU Staff and

rd degree bund degree ane made by th

e followingyears of ageyears of agers of age wit

on to Acute Cto your ACU

e of admissioeriod of time

8 years of ag

wn renal disor a urine ouod of observa

n chronic ree or pre-admhours) will b

nal failure o

ass C liver d

ests for pregof standard

intestinal ocdered a cont

m high voltag

uld be qualifproper conducal staff are

ing on the Rconducted e

urns requirind/or deep 3he surgeon/p

3 criteria:e with TBSA e with TBSA th TBSA > 1

Care Unit (AU. If a patienton to your une at another f

ge

sease, renal utput of less ation is not a

enal failure mission creabe required.

on dialysis w

disease

gnancy will bof ACU prac

cclusion or praindication

ge electrical

fied by educuct of the triadequately

RE-ENERGIZeither in pers

ing grafting3rd degree bphysician.

> 20% > 15% WIT

10%

ACU) to timet is transferrnit. An excepfacility post b

dysfunctionthan 500 mlavailable).

(pre-dialysisatinine or a u

will be exclu

be done on actice)

perforation, ifor Enteral N

contact.

cation, traininal. The Site trained in G

ZE study. Stson or via we

g burns requirin

H inhalation

e of consent red from anoption would burn prior to

n defined as l/last 24 hou

s), an absoluurine output

uded.

all women of

intra-abdomNutrition).

8

ng and Investigator

GCP (GCP 4

tudy specificebinar.

ng grafting is

injury

other facility,be a patient

o admission

a serum urs (or 80 ml/

ute increase of <500 ml/l

f childbearin

inal injury.

r is .1.1).

c

s an

the t who to

/last

of ast

ng

Version 1

8) P

ofN

9) P

Idmin

10) E

nsyto

11) R

Trag

12) K

InvestiThe activand cont NutrestoNutrestosyndromfunctionsconditionfrom endrequiremsignificanGlutamincatabolicamino ac Maltrin® The MALthen pacpharmac(GRAS) apracticesand suitamaltodexcommon

1.2b: 09-Fe

Patients who f the Site Inv

Note that an i

Patients with deally BMI sh

may be somencluding the

Enrollment inon-randomizynopsis or ao which you

Received gluThis refers toandomizationlutamine, dis

Known allerg

igational ve and contrrol have the

ore (L Glutre is an amine by the FDA

s in regulations, glutaminedogenous gluments for glutntly from thene concentrac disease stacid.

M100 MaltoLTRIN® M10kaged by An

ceutical gradas direct hums. They are pable acids anxtrin (controlly found in s

b-2016

are moribunvestigator orisolated DNR

extreme bodhould be cal

e subjectivitypatient.

another indzed academ

abstract of thwould like to

tamine suppo consistent an. If the patiscontinue th

y to maltode

Product rol products w same visua

tamine) no acid (L GA. L Glutam

on of gastroine concentratutamate. Datamine durin

e role of and ations decreaates, and thu

odextrin (co0 maltodextnderson Pace, white carbman food ingprepared as nd/or enzym) mixed with

standard ent

nd (not exper delegated dR does not f

dy sizes: BMlculated usiny involved in

dustry sponsmic studies whe study to tho co-enroll.

plement for >administratioient receivedhe glutamine

extrin, corn s

will both be

al appearanc

Glutamine) poine is produntestinal celtion is maintata from clinic

ng burns, catnutritional re

ase and tissus glutamine

ontrol) rin is produc

ckaging for tbohydrate pgredients at a white pow

mes. Patientsh water or oteral nutrition

ected to survdoctor in chafulfil this crite

MI < 18 or > ng the patienthe determi

ored ICU intwill be approvhe project le

> 24 hours pon of glutamd random or e prior to ran

starch, corn,

supplied in pce and taste.

owder that isced normallyl growth, funained in the cal studies itabolic illnesequirementsue glutamine

e is often con

ced by Grainhe trial. Maltowders thatlevels cons

wder by partis will receiveher liquids. Mn and has no

vive the nextarge). eria.

50 kg/m2 nt’s pre-burnination of BM

tervention stved. For acaeader to obta

prior to randomine over the

intermittent domization.

corn produc

pre-package.

s approved fy by the bod

nction, and rebody by diendicate that

ss, trauma, as for glutamie metabolismnsidered a "c

n Processingtodextrins arare Genera

istent with cal hydrolysis

e an iso-caloMaltodextrino metabolic

t 72 hours in

n dry weight.MI, err on the

tudy (co-enrademic RCTsain pre-appro

omization. e 24 hr periodoses of op

cts or glutam

ed 5g packe

for oral use dy and has imegeneration

etary intake athe role of a

and infectionne in healthym increasesconditionally

g Corporatiore bland, low

ally Recognizcurrent good s of corn sta

orically deliven is a sourceeffects othe

9

n the judgem

. Given that e side of

rollment in aTs, forward a

oval of the s

od prior to pen label

mine.

ts. The activ

in short bowmportant

n. Under normand synthesand nutritionn may differ y individuals

s during many essential"

n (GPC) andw sweetnesszed As Safemanufactur

arch with safered amounte of carbohydr than servin

ment

there

ll

study

ve

wel

mal sis nal

s. ny

d s, e ring fe t of drate ng as

Version 1

a source calories p Dosing Study intrecordedwith the u Patients enterally

a) Pb

b) P(m

Ad

The patieused for clinically interventAssociate

Duratio Patientssuccessacute ca We recogmay not difficult totheir illnephase.

Standa

We recomPractices Given theprovisionburn unitthe outco

1.2b: 09-Fe

of additionaper 5g packe

tervention wd in the eCRFusual weight

will receive or TID to Q

Patients with ased on pre

Patients with maltodextrin

djusted Bod

ent’s IP dosidrug dosingsignificant cion dose adjed data will

on

will receivesful graftingare unit adm

gnize that debe very exao define. As ess and eithe

ardization

mmend all ss.

e metabolic n of nutrition ts exists1. Toomes of The

b-2016

al energy. Thet.

ill be dosed F. By dry wet recorded o

glutamine oID if po, for a

a BMI <35 we-burn dry we

a BMI >35 w) based on t

dy Weight (A+ [(p

ng weight sh. If the clinic

change in thejusted in accbe recorded

e the study g operation,mission, wh

efining the ect or preciseguidance, w

er discharge

n of Nutri

study patient

complicationsupport is a

o reduce thee RE-ENERG

he maltodex

in accordaneight, we meon a prior cha

r maltodextra total of 0.5

will receive 0eight (actualwill receive 0the adjusted

ABW) = Ideapre-burn dry

hould only bcal team chae patient’s wcordance witd in the eCR

interventio or until acuatever com

end of study e. There maywe generallyed from the a

ition Prac

ts be fed in a

ns and increa challenginge effect of vaGIZE study,

trin used in t

ce with the pean prior to rart or obtain

rin through th5 g/kg/day.

0.5 g/kg/dayl or estimate0.5 g/kg/day body weigh

al Body Wey weight – I

be changed Ianges the weweight, the pth the patienF.

on from randute care unes first.

treatment phy be unique

y mean whenacute care un

ctices

accordance w

eased nutritiog task and varying nutritioit is importan

this study co

patient’s preresuscitationed from a fa

heir feeding

y of either glued). y of either gluht, as per ca

eight (IBW) IBW) x 0.25]

IF the clinicaeight used fo

pharmacy wilnt’s current d

domizationit discharge

hase by 7 dafeatures to s

n the patientnit or enterin

with the Sta

onal requiremariability in nonal practicent to standa

ontains appr

e-burn dry wn and it is likeamily membe

tube, every

utamine or m

utamine or plculation bel

based on a]

al team chanor drug dosinll be notifieddrug dosing

until 7 daye, or until 3

ays post lassome patient is over the ng in their re

ndardization

ments in burnutrition praces as confourdize, as mu

10

roximately 1

weight and ely consisteer.

4 hours

maltodextrin

placebo ow.

BMI of 25

nges the weing due to a and the stuweight.

ys post last 3 months aft

st successfulnts that makeacute phase

ehabilitation

n of Nutrition

rns patients,ctices acrossunding factoruch as possi

9

nt

ight

udy

ter

l graft e it e of

n

, the s rs on ible,

Version 1

the prescto withhopatients. Based onparticipatall patienranges b

1) P

ep

Uous

2) P

A

PpaIf

3) Vb

1.2b: 09-Fe

cription of enolding feeds

n the literatuting sites, we

nts enrolled ibelow will allo

Prescribed Equation, or arescription o

Use pre-burnbesity, followse the formu

Adjusted

Prescribed P

According toi. ii.

re-burn dry atients, if yoyou do not

Adjusted

Vitamin & Mlood levels

• • • • • • • • • •

b-2016

nteral and pafor high gas

ure and prove are recomn the study.ow for most

Energy needa simple weiof less than 3

dry weight. w your standula below.

Body Weigh+

Protein need

o % burn suIf > 50% bIf < 50% b

weight* shoour standard have an obe

Body Weigh+

ineral Presc(if blood teVitamin C:Vitamin A: Vitamin D:Vitamin E: Zinc (not eCopper SuSelenium: MagnesiumFolate: 0-1Thiamin: 0

arenteral nutstric residual

iding for sommmending co

After reviewcurrent prac

ds are to beight-based fo30 kcal/kg.

For Obese dard practice

ht (ABW) = + [(pre-burn

ds are to be

urface area urns, use 1.urns, use 1.

uld be used practice is t

esity adjustm

ht (ABW) = + [(pre-burn

cription shoesting is do 0-1000 mg/ 0-10,000 IU according t0-420 mg/d

elemental): 0ulfate: 0-4.5 0-500 micro

m:0-600 mg/1500 mg/day0-110 mg/day

trition, microvolumes an

me flexibility ompliance wiwing the pracctices to con

e calculatedormula but o

patients, if ye. If you do

Ideal Body n dry weight

e calculated

5 g/kg*/day 2 g/kg*/day

when calcuto adjust for ment practice

Ideal Body n dry weight

ould be givene as part o/day U/day o serum leve

day 0-220 mg/damg/day

ograms/day/day y y

onutrient delnd use of mo

for current pith the followctices at all t

ntinue.

d using Indiron average,

your standanot have an

Weight (IBt – IBW) x 0

d using the

to 2.5g/kg*/y to 2 g/kg*/d

lating proteiobesity, follo

e, use the fo

Weight (IBt – IBW) x 0

en as followof routine p

els

y

ivery and protility agents

practices acwing nutritionthe participa

rect Calorimshould not l

rd practice is obesity adju

W) based o0.25]

following:

/day day

n needs. Foow your stan

ormula below

W) based o0.25]

ws or depenpractice) :

11

ractices relats in these

cross the nal practicesating sites, th

metry, a predead to a

s to adjust foustment pra

on a BMI of

or Obese ndard practicw.

on a BMI of

nding upon

ted

s for hese

ictive

or ctice,

25

ce.

25

Version 1

Earlyis a

T

T

4) S

5) O

TInstmreain Oeof

6) GTbreia

1.2b: 09-Fe

ly supplemeallowed 2. S

These rangeover an

These rangesThis mea

subtrac

Specialized

i. Arginine• •

ii. Glutami

• • • •

Form

OptimizationThe use of ennterruptions trategies to o

minimum of 4esidual volumcceptable), a

ndicated. Re

Ongoing monnsure that thf the study p

Glycemic coThe use of a

etween the ecommendeatrogenic hyp

To minimglutamine

b-2016

entation by Standard mu

es of vitaminsnd beyond w

s of vitaminsans that the cted from the

nutritional f

e enriched foPivot® (13Perative (8

ine supplemImpact® GVIVONEX®GLUTASOJuven® (7

mulas with gl

n of the Delinteral nutritioto the deliveoptimize the

45 degrees (me thresholdand the use

efer to Entera

nitoring of thhe recommeprotocol.

ontrol: glycemic coranges of at

ed in order topoglycemia

mize any potfor >24 hrs

high dose Iultivitamin/m

s/minerals/trwhat is prese

s/minerals/traamounts rece total range

formulas ar

ormulas (for3 g/L) 8 g/L)

ments or formlutamine (15

® Plus (13.5 LVE® (15 g/g/L)

utamic acid

ivery of Enton is preferreery of enterae delivery of (unless othed of 250 ml (of motility a

al Feeding P

e volumes oended prescr

ontrol protocot least 80 mgo avoid hypeand other ha

tential contbefore rand

IV Vitamin Cmineral pre

race elemenent in the sta

OR ace elementceived from es and the re

re not allow

mulas that c

mulas enriche5 g/L) g/L)

/L)/other glu

inherently p

teral Nutritioed over pare

al nutrition shEN such as rwise contra(if you use a

agents and sProtocol in th

of delivery ofribed needs

ol (or the useg/dL to a maerglycemia, warms associ

tamination, domization,

C (66 mg/kgeparations a

nts may be pandard enter

ts may be prenteral/pare

emainder is g

wed such as

contain argin

ed with gluta

utamine pow

present are a

on: enteral nutrithould be minelevating th

aindicated), ua larger GRVsmall bowel fhe Appendix

f enteral nutrare being m

e of insulin) aximum of 18while minimiated with a

patients th, should NO

g/hr) within are allowed

provided as sral/parentera

rovided as thenteral nutritgiven as sup

s:

nine > 6 g/L)

amine, eg:

wders

allowed

tion in burn pnimized whilhe head of thusing a mini

V threshold, feeding tube

x A for more

rition and anmet is recom

to control b80 mg/dL (4zing the risklower blood

hat have recOT be includ

12

the first 48(IV, NG or p

supplementaal nutrition.

he total amotion are to bepplements.

), eg:

patients. e adopting he bed to a mum gastricthat is

es as clinicaldetails.

n action planmended as

lood sugars .4-10 mmol/

k of both glucose targ

ceived ded.

8 hrs po).

ation

ounts. e

c

lly

n to part

/L) is

get.

Version 1

Data C Data for last succ Worksheconveniechart, pleEDCS.

NutritionPrescribeRecord tassessedthe ACU

• C• P

Record tRecord t If the enenew presbelow).

Enteral aRecord tthe date form (exa

IF THENOTE

1.2b: 09-Fe

Collection

the RE-ENEcessful graft,

eets for colleence. Whethease ensure

n Assessmeed Energy ahe date in thd by the diet. If prescript

Calories = 25Protein = 1.2

he energy phe protein p

ergy and proscription for c

and Parenterhe start andand time ENample below

E PRESCRIPTE: ENERGY A

DO NOT

b-2016

n

ERGIZE stud ACU discha

cting data reer recording the researc

ent/Timing (nd Protein N

he Baseline Atitian, or phyion informat

5 kcal/kg/day2 g/kg/day

rescribed in rescribed in

otein prescripcalories and

ral Start and stop date a

N and PN wew). Do not re

TION CHANGEAND PROTEIN

T CHANGE PR

dy are to be arge, or 3 m

elated to nutg data on thech coordinato

(see AppenNeeds Assessment

ysisican if noion is not avy

kcals grams

ption changed protein on t

d Stop Datesnd time of b

ere stopped cord tempor

ES FOR THIS PREQUIREMEN

RESCRIPTION

collected froonths from A

tritional assee worksheet or has acces

ndix B)

t box that theo dietitian avavailable, we w

es during thethe Nutrition

s and Timesboth Enteral a

permanentlyrary interrup

PATIENT, ENTNTS ARE INDE

N TO ACCOMM

om ACU admACU admiss

essment andor completin

ss to the info

e initial enerailable, afterwill use the f

e study perion Assessmen

and Parentey on the Nut

ptions.

TER THE DATEEPENDENT OMODATE FOR

mission throusion, whiche

d adequacy ang the data ormation for

rgy and protr the patient following:

od, record thnt/Timing for

eral Nutritiontrition Asses

E AND NEW POF FORMULA PRMULA CHANG

13

ugh 10 daysver comes f

are providedin the patienentry into th

tein needs wwas admitte

he date and rm (example

n. Only recorssment / Tim

PRESCRIPTIONPRESCRIBEDGE.

s post first.

d for nt’s he

were ed to

the e

rd ming

N: D.

Version 1

• In

a• If

st• If

a

Daily NuEnteral NRecord tIndicate w If EN wasEN on th

• N• N• N• H• In• V• D

1.2b: 09-Fe

ndicate if theppropriate b

f EN/PN is ctop date andf the patient ppropriate b

utrition ReceNutrition (ENhe date. whether or n

s not receive specified d

NPO for endoNPO for operNPO for radioHigh NG draincreased ab

Vomiting, emDiarrhea

b-2016

e patient recbox. continued bed time. is still recei

box.

eived (see AN)

not the patie

ed, using thday: otracheal exrating procedology procednage dominal girtesis, or nau

eived EN/P

eyond ACU

iving EN/PN

Appendix C

nt received

e list below,

xtubation or idure dure

h, abdominasea

N during this

U discharge

N in the ACU

C)

EN that day

indicate all

ntubation or

al distention,

s ACU admi

, record ACU

U at 3 mont

y by marking

the reasons

r other beds

, or patient d

ission, by ma

U discharge

ths, indicate

Yes or No.

s the patient

ide procedu

discomfort

14

arking the

as the EN/P

e by marking

did not rece

re

PN

the

eive

Version 1

• N• In• P• O• R• O

If EN was

• E• E• E

Protein SIndicate win the PR

• E• E• E

ParenterIndicate w If PN was

• E• E

IV FluidsIndicate wYes or N If IV fluid

• E Oral IntaIndicate w Propofol Indicate wday by m If a conti

• E

1.2b: 09-Fe

No enteral acnotropes, va

Patient deemOn oral feedsReason not kOther, please

s received: Enter the namEnter the totaEnter the tota

Supplementswhether or n

ROTEIN SUPEnter the namEnter the totaEnter the tota

al Nutrition (whether or n

s received: Enter the totaEnter the tota

s containing whether or no.

containing gnter the tota

ke whether or n

whether or nmarking Yes

nuous infusiEnter the volu

b-2016

ccess availabsopressor re

med too sick fs known e specify: __

me(s) of the al kcals receal grams of p

s not the patiePPLEMENT me of the sual kcals receal grams of p

(PN) not the patie

al kcals receal grams of p

Glucose not the patie

glucose wasal kcals rece

not the patie

not the patieor No.

on of Propoume of Prop

ble/enteral aequirementfor enteral fe

___________

formula(s) (ived from EN

protein recei

nt received row. If a pro

pplement ived from th

protein recei

nt received

ived from PNprotein recei

nt received

s received: ived from IV

nt received

nt received

fol for > 6 hopofol receive

access lost, d

eeding

_______

up to 3 formN ved from EN

a protein suotein supple

e protein suved from the

PN that day

N ved from PN

IV fluids con

V fluids

oral nutrition

a continuous

ours was recd in mL.

displaced, o

mulas)

N

pplement thment was re

upplement e protein sup

y by marking

N

ntaining gluc

n that day by

s infusion of

ceived:

or malfunctio

hat day by meceived:

pplement

Yes or No.

cose that day

y marking Ye

f Propofol fo

15

oning

marking Yes o

y by marking

es or No.

or > 6 hours t

or No

g

that

Version 1

Appen Appendix Appendix Appendix

1.2b: 09-Fe

ndices

x A: Enteral

x B: Nutritio

x C: Daily N

b-2016

Feeding Pr

onal Assessm

Nutrition form

rotocol

ment/Timing

m

form

16

Version 1

Append

1.2b: 09-Fe

dix A: Ente

b-2016

ral Feeding Protocol

l

17

Version 1

Append

1.2b: 09-Fe

dix B: Nutr

b-2016

ition Assesssment/Tim

ming Formm

18

Version 1

Appendi

1.2b: 09-Fe

ix C: Daily N

b-2016

Nutrition Foorm

19

Version 1

Refere 1 Masters Jul-Aug;2 2 TanakaBurned Patient 2000;13

1.2b: 09-Fe

ences

B, Wood F. N9(4):561-71.

H, Matsuda T

s Using Asco35:326-331

b-2016

Nutrition supp

T, Miyaganta

orbic Acid Adm

port in burns--

ni Y, et al.Re

ministration. A

-is there cons

duction of Re

A Randomize

sistency in pra

esuscitation F

ed, Prospectiv

actice? J Burn

Fluid Volumes

ve Study. Arc

20

n Care Res. 2

s in Severely

ch Surg.

2008